Shares of CARSGEN-B (02171) experienced a notable rise during the afternoon session, gaining over 3%. At the time of writing, the stock was up 2.9%, trading at HK$12.78 with a turnover of approximately HK$96.09 million.

The upward movement follows the company's midday announcement that its board has approved a share repurchase initiative. The plan authorizes the buyback of up to approximately 30.12 million shares, representing about 5% of the total issued shares as of May 31, 2026. This repurchase program is scheduled to run from June 25, 2026, until the conclusion of the next annual general meeting.

Funding for the share repurchases will be sourced from non-IPO proceeds, including revenue from business operations, interest income, and other subsidies.

This development comes shortly after the company announced that the new drug application for its self-developed Claudin18.2 autologous humanized CAR-T cell therapy product, "Kailimei" (Surocelio's injection), has been approved by China's National Medical Products Administration. The list price for Kailimei has been set at 990,000 yuan per treatment, a figure determined after considering factors such as the pricing of other commercially available CAR-T products, epidemiology, and payment considerations.